Financial Performance - Revenue for Q3 2022 was CNY 117,449,975.50, a decrease of 22.98% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 8,655,549.55, down 29.23% year-on-year[5] - Basic earnings per share decreased by 45.00% to CNY 0.11[5] - Total operating revenue for the third quarter of 2022 was RMB 302,488,326.43, a decrease of 23.7% compared to RMB 396,422,129.81 in the same period last year[20] - The net profit for Q3 2022 was CNY 21,603,579.65, a decrease of 54.4% compared to CNY 47,286,377.81 in Q3 2021[22] - Operating profit for Q3 2022 was CNY 25,513,696.96, down 52.2% from CNY 53,415,641.67 in the same period last year[22] - Total revenue from operating activities was CNY 368,629,443.63, a decline of 18.4% compared to CNY 451,532,964.63 in Q3 2021[26] - The total comprehensive income for Q3 2022 was CNY 21,603,579.65, significantly lower than CNY 47,286,377.81 in Q3 2021[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 887,414,836.06, an increase of 4.23% from the end of the previous year[5] - The total assets of the company as of September 30, 2022, were RMB 887,414,836.06, compared to RMB 851,423,622.82 at the beginning of the year, an increase of 4.2%[20] - The total liabilities increased to RMB 130,174,324.76 from RMB 62,789,771.85, indicating a significant rise of 107.0%[19] Cash Flow and Investments - The company's cash and cash equivalents decreased to RMB 534,621,907.83 from RMB 610,930,333.64 at the beginning of the year, a decline of 12.4%[17] - The cash flow from operating activities showed a net outflow of CNY 27,158,694.67, contrasting with a net inflow of CNY 39,546,864.33 in the previous year[26] - Investment activities resulted in a net cash outflow of CNY 156,733,060.83, compared to a smaller outflow of CNY 3,993,603.56 in Q3 2021[27] - The cash and cash equivalents at the end of Q3 2022 stood at CNY 311,890,955.77, down from CNY 637,379,375.20 at the end of Q3 2021[27] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,012[11] - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 58.35% of the shares[11] Operational Metrics - Operating costs rose by 60.35% due to changes in product structure[9] - Total operating costs amounted to RMB 288,836,450.34, down from RMB 346,559,133.52, reflecting a reduction of 16.7% year-over-year[20] - Research and development expenses were RMB 13,101,570.92, down from RMB 17,360,705.80, a decrease of 24.9% year-over-year[20] - The company reported a significant increase in accounts receivable financing by 159.41% due to the receipt of bank acceptance bills[9] - Accounts receivable decreased to RMB 87,790,835.03 from RMB 98,290,746.40, representing a reduction of 10.2%[17] - Inventory increased by 40.70%, primarily due to an increase in stock[9] - Inventory increased to RMB 13,822,877.74 from RMB 9,824,013.58, marking a rise of 40.1%[17] Other Income and Expenses - Other income increased by 152.51% as a result of higher government subsidies received[9] - The company reported a decrease in other income to CNY 11,683,038.23 from CNY 4,626,692.22 in the previous year[22] - The company experienced a credit impairment loss of CNY -2,798,232.37, worsening from CNY -1,061,861.24 in Q3 2021[22] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.28, a decrease from CNY 0.82 in the same quarter last year[23]
多瑞医药(301075) - 2022 Q3 - 季度财报